# TABLE OF CONTENTS

About Gairdner..........................................................2
Greetings from the Chair.............................................3
Greetings from the President & Scientific Director............4
2017 Year in Review..................................................5
  2017 Canada Gairdner Award Laureates.......................6
  2017 Student Outreach Program..................................7
  2017 National Program...........................................9
  2017 Canada Gairdner Symposia................................11
  Additional 2017 Programming...................................13
2017 Gairdner Foundation Supporters...........................15
The Year Ahead: Objectives for 2018.............................16
Governance.....................................................................17
  2017 Board of Directors............................................17
  2017 Standing Committees of the Board.......................18
Gairdner Foundation Committees.................................18
  Medical Review Panel..............................................18
  Medical Advisory Board..........................................19
  Wightman Award Advisory Committee........................20
  Global Health Award Advisory Committee.....................21
2017 Financial Highlights...........................................22
Gairdner Foundation Staff............................................24
Auditor’s Report.......................................................Attached
ABOUT GAIRDNER

History

The Gairdner Foundation was established in 1957 to award annual prizes to individual researchers whose discoveries in biomedical science have had major impact on progress in science and on human health. Annually, seven awards are given: five Canada Gairdner International Awards, for excellence in biomedical research, the John Dirks Canada Gairdner Global Health Award, for outstanding achievements in Global Health research, and the Canada Gairdner Wightman Award, reserved for a Canadian scientist demonstrating exceptional leadership in Canadian medical science. The Awards are highly regarded as one of the world’s most prestigious biomedical prizes with many of our laureates (87 in our history) going on to receive the Nobel Prize.

Mission

- To **celebrate excellence** in fundamental research that impacts human health through the Canada Gairdner Awards
- To **convene leaders** from the research, academic, public and private sectors through events
- To **inspire the next generation** of students in the excitement and potential of scientific research in a global context through outreach programs
MESSAGE FROM THE CHAIR

The Gairdner Foundation continues to be a leading Canadian scientific organization with global reach. Our excellent media coverage, participation in our outreach programming and quality of nominations and awardees is a testament to the strength and reputation of the Gairdner brand.

The decision to recognize seven different research areas in 2017 brought a variety to the National and Student Outreach Programs that engaged audiences on university campuses from coast to coast. In addition, Gairdner also took on a new challenge I am particularly proud of, the Canada Gairdner Public Lecture Series bringing a new audience into the Gairdner fold. As our laureates travelled across the country, they cultivated and inspired the next generation of researchers, innovators and leaders with stories of their careers and advice on how to make the most out of a passion for science.

This year was a special year for Gairdner as we awarded two Canadian scientists for their outstanding research. We were proud to promote the strength of scientific research in Canada and celebrate world-renowned work that has local, national and international impact.

The 2017 Canada Gairdner Laureates’ Lecture was an inspiring display of scientific research that truly affects the lives of people all around the world. Discussions of child and maternal health, statins and vaccines attracted a large and diverse audience as each of the laureates presented their award-winning research at the University of Toronto. Following the Laureates’ Lectures, awardees and their families joined members of the healthcare, academic and corporate sectors in a formal celebration of their achievements at the awards gala, which is always a highlight of the annual Gairdner programming.

I would like to extend my sincere thanks to the Government of Canada and CIHR, and the Governments of Ontario, Québec and Alberta for their generous support of the Gairdner Foundation.

In 2017, as in every year, I am proud to be the Chair of the Gairdner Foundation’s Board of Directors. The dedicated team at Gairdner and the committed volunteers across Canada bring an energy to the Gairdner mission that helps us continue to be Canada’s most prestigious prize in biomedicine.

D. Lorne Tyrrell, OC, AOE, MD/PhD, FRCP, FRSC
Chair, Gairdner Board of Directors
MESSAGE FROM THE PRESIDENT & SCIENTIFIC DIRECTOR

2017 was a great year for the Gairdner Foundation as we recognized and celebrated outstanding scientists from seven distinct fields of research including vaccinology, child and maternal health, stroke and cardiac disease, somatosensation, NMR and autism spectrum disorders.

As part of our annual outreach programming the 2017 laureates travelled across the country sharing their stories and research with faculty, trainees and high school students. With such a fantastic array of research to share, the laureates captivated audiences in all provinces. In fact, in 2017 we had over 10,000 participants in our outreach programming- more than any other year in Gairdner history!

In addition to our traditional outreach programming, Gairdner launched its inaugural public lecture series that brought together members of the public to hear from world-class scientists. As Gairdner continues to expand its programming each year, particular emphasis has been placed on engaging the public with science that affects their everyday lives. Gairdner wants to reinforce its mission to inspire the next generation of researchers, thinkers and scientific leaders by providing public opportunities to engage with research. Gairdner will build on its first year of public lectures with a further expanded series in 2018.

The annual Awards Gala welcomed more than 500 guests from the research, academic, public and private sectors to the Royal Ontario Museum. Minister of Health, Ginette Petitpas Taylor addressed the audience, emphasizing the Government of Canada’s strong support for the Foundation and our impact around the globe.

As we do each year, the Gairdner Foundation hosted international receptions in celebration of our laureates. Gairdner held these events in partnership with the University of Ottawa, University of Toronto and SickKids Hospital, the Texas Children’s Hospital, the University of California San Francisco, University of Siena and GSK and the Canadian Embassies in Tokyo and Rio de Janeiro. The receptions were a great success. Gairdner strengthened its international presence and established relationships that will expand our partnership opportunities, nominations and build our brand on the world stage.

Countless volunteers give their time and energy to further the Gairdner mission. I am very grateful to the members of our awards adjudication committees for their tireless efforts to select the world’s most deserving scientists as Canada Gairdner Award laureates. I am also grateful for the volunteers at our many university partners who facilitate our National and Student Outreach program on their campuses. I’d also like to express my gratitude to our many sponsors and supporters, our Gairdner staff and Board of Directors who embody the Gairdner mission and whose hard work and dedication is the backbone of everything we do.

\[signature\]

Dr. Janet Rossant, CC, PhD, FRS, FRSC
President and Scientific Director, Gairdner Foundation
2017 YEAR IN REVIEW

Report on 2017 Objectives

1. Enhance participation in the National Program & build on success of past Student Outreach activities
   - In 2017, Gairdner added two more universities to our National Program lecture circuit and to our Student Outreach Program
   - Gairdner extended the opportunity to live webcast programming to all universities
   - Universities added more individualized programming to their Gairdner events, hosting faculty and trainee receptions, mentoring sessions etc.

2. Enhance the international profile of the Canada Gairdner Awards
   - In 2017, Gairdner promoted its John Dirks Canada Gairdner Global Health Award Laureate at the annual conference for the Consortium of Universities for Global Health where Dr. Cesar Victora delivered a keynote address
   - Gairdner also held receptions in each of the home cities of the laureates

3. Continue to increase the number and quality of the nominations
   - In 2017, Gairdner made a concerted effort to seek nominations from all over the world
   - In 2017 (and continuing in the future) Gairdner placed special emphasis on sourcing competitive nominations of members of groups underrepresented in scientific awards and in the research community at large, including but not limited to women, visible minorities, indigenous persons and individuals with disabilities
   - Gairdner sent calls for nominations to many international research and academic bodies including the Association of Schools and Programs of Public Health (USA), The Association of Schools of Public Health in the European Region, Asia Pacific Academic Consortium for Public Health, the Latin American Alliance for Global Health, The Association of Schools of Public Health in Africa, The Federation of European Societies for Tropical Medicine and International Health

4. Partner in two special high quality symposia in various parts of Canada each year
   - Gairdner hosted its annual symposia in Alberta and Ontario in partnership with the University of Calgary, University of Alberta and York University

5. Engage a broader audience through an enhanced public lecture series
   - In 2017, Gairdner launched its inaugural Canada Gairdner Public Series which attracted nearly 1,000 attendees
   - The lecture series took place in Toronto and in Montréal where the lecture was delivered in French

"As a Canada Gairdner Award laureate, I’ve had the opportunity to share my passion for science with high school, university, and graduate students through the Foundation’s fantastic outreach program. What a great way to celebrate this exciting moment!"

- Dr. David Julius, 2017 Canada Gairdner International Award laureate
2017 CANADA GAIRDNER AWARD LAUREATES

(2017 Laureates listed below from left to right)

Dr. Akira Endo (Pictured: Dr. Keiji Hasumi, accepting the Award on Dr. Endo’s behalf)

Canada Gairdner International Award
“For the first discovery and development of statins, inhibitors of cholesterol biosynthesis that have transformed the prevention and treatment of cardiovascular disease”

Dr. Rino Rappuoli

Canada Gairdner International Award
“For pioneering the genomic approach, known as reverse vaccinology, used to develop a vaccine against meningococcus B which has saved many lives worldwide”

Dr. Cesar Victora

John Dirks Canada Gairdner Global Health Award
“For outstanding contributions to maternal and child health and nutrition in low and middle income countries, with particular focus on the impact of exclusive breastfeeding on infant mortality and on the long-term impact of early-life nutrition”

Dr. Huda Zoghbi

Canada Gairdner International Award
“For the discovery of the genetic basis of Rett syndrome and its implications for autism spectrum disorder”

Dr. Lewis E. Kay

Canada Gairdner International Award
“For the development of modern NMR spectroscopy for studies of biomolecular structure dynamics and function, including applications to molecular machines and rare protein conformations”

Dr. Antoine M. Hakim

Canada Gairdner Wightman Award
“For outstanding research into strokes and their consequences and championing stroke prevention and treatment in Canada and beyond”

Dr. David Julius

Canada Gairdner International Award
“For determining the molecular basis of somatosensation- how we sense heat, cold and pain.”
**GAIRDNER’S 2017 STUDENT OUTREACH PROGRAM**

As part of Gaardner’s mission to inspire the next generation of researchers, the Gaardner Foundation hosts outreach programming for high school students at partner universities from coast to coast. The lectures, which focus on each laureate’s personal journey in research, serve to ignite a passion for science that we hope translates into increased enrolment in science programs at the post-secondary level. The lectures also give students the opportunity to interact with laureates and learn more about their career and accomplishments. Many laureates cite the Student Outreach Program as their favourite part of receiving the Canada Gaardner Award, and student response is uniformly enthusiastic.

**In 2017, the Student Outreach Program reached over 3,000 students from 111 high schools at 18 partner universities**

<table>
<thead>
<tr>
<th>Date (2017)</th>
<th>Location</th>
<th>Speaker</th>
<th>Lecture Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 9</td>
<td>Lakehead University</td>
<td>Dr. Adrian Owen, CERC in Cognition and Neuroimaging, Western University; Member Canada Gaardner Award Medical Review Panel</td>
<td>The Search for Consciousness: Detecting Awareness in the Vegetative State</td>
</tr>
<tr>
<td>September 25</td>
<td>Université de Sherbrooke</td>
<td>Dr. Jack Szostak, Professor of Genetics at Harvard Medical School, Cambridge, Mass.</td>
<td>Advances in Nonenzymatic Template-Directed Primer Extension</td>
</tr>
<tr>
<td>October 19-20</td>
<td>University of Lethbridge</td>
<td>Dr. Lewis Kay, 2017 Canada Gaardner International Laureate, University of Toronto</td>
<td>Watching Proteins Dance Using Biophysics</td>
</tr>
<tr>
<td>October 20</td>
<td>Université Laval</td>
<td>Dr. Antoine Hakim, 2017 Canada Gaardner Wightman Laureate, University of Ottawa</td>
<td>Préservez Votre Vitalité Mentale: Les AVCS et la Démence sont évitables</td>
</tr>
<tr>
<td>October 23</td>
<td>University of British Columbia</td>
<td>Dr. Huda Zoghbi, 2017 Canada Gaardner International Laureate, Baylor College of Medicine, Houston, Texas; Dr. Rodolphe Barrangou, 2016 Canada Gaardner International Laureate, North Carolina State University, Raleigh, NC</td>
<td>A Career in Balance; The many hats scientists wear</td>
</tr>
<tr>
<td>October 23</td>
<td>University of Alberta</td>
<td>Dr. Lewis Kay; Dr. David Julius, 2017 Canada Gaardner International Laureate, University of California San Francisco, San Francisco, CA</td>
<td>Watching Proteins Dance Using Biophysics; How spices helped us understand pain sensation (...and why science matters)*</td>
</tr>
<tr>
<td>October 23</td>
<td>University of Winnipeg</td>
<td>Dr. Lynne Maquat, 2015 Canada Gaardner International Laureate, University of Rochester, Rochester, NY</td>
<td>On being a scientist: Making a difference in the world</td>
</tr>
<tr>
<td>October 23</td>
<td>Western University</td>
<td>Dr. Rino Rappuoli, 2017 Canada Gaardner International Laureate, Chief Scientist and Head External R&amp;D, GSK Vaccines, Siena, Italy</td>
<td>Doing Science, Saving Lives</td>
</tr>
<tr>
<td>October 24</td>
<td>Université de Montréal</td>
<td>Dr. David Julius</td>
<td>How spices helped us understand pain sensation (...and why science matters)*</td>
</tr>
<tr>
<td>October 24</td>
<td>Carleton University</td>
<td>Dr. Cesar Victoria, 2017 John Dirks Canada Gaardner Global Health Laureate, Emeritus Professor, Federal University of Pelotas, Pelotas, Brazil</td>
<td>Why do research in epidemiology?</td>
</tr>
<tr>
<td>Date</td>
<td>Institution</td>
<td>Speaker(s)</td>
<td>Title</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>October 24</td>
<td>University of Calgary</td>
<td>Dr. Lewis Kay</td>
<td>Watching Proteins Dance Using Biophysics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Huda Zoghbi</td>
<td>A Career in Balance</td>
</tr>
<tr>
<td>October 24</td>
<td>University of Waterloo</td>
<td>Dr. Rino Rappuoli</td>
<td>Doing Science, Saving Lives</td>
</tr>
<tr>
<td>October 24</td>
<td>University of Saskatchewan</td>
<td>Dr. Lynne Maquat</td>
<td>On being a scientist: Making a difference in the world</td>
</tr>
<tr>
<td>October 25</td>
<td>York University</td>
<td>Dr. David Julius, Lea Harrington, Université de Montréal, Institute of Research in Immunology and Cancer (IRIC), Montréal, QC</td>
<td>How spices helped us understand pain sensation (and why science matters)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chromatin and stem cell cell fate are impacted globally by short telomeres</td>
</tr>
<tr>
<td>October 27</td>
<td>University of Toronto</td>
<td>Dr. Huda Zoghbi, Dr. Cesar Victoria</td>
<td>A Career in Balance</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Why do research in epidemiology?</td>
</tr>
<tr>
<td>November 1-2</td>
<td>University of New Brunswick</td>
<td>Dr. Janet Rossant, 2015 Canada Gairdner Wightman Laureate and President The Gairdner Foundation</td>
<td>The Winding Road To Becoming A Stem Cell Biologist</td>
</tr>
<tr>
<td>November 14</td>
<td>McGill University</td>
<td>Dr. Lewis Kay</td>
<td>Watching Proteins Dance Using Biophysics</td>
</tr>
<tr>
<td>November 15-16</td>
<td>Memorial University</td>
<td>Dr. Lewis Kay</td>
<td>Watching Proteins Dance Using Biophysics</td>
</tr>
</tbody>
</table>

**Student Impact: Miranda Li**

“It can be hard to figure out how to become the accomplished scientists and researchers you read about. The gap between what you are doing and where they are can seem so big and figuring out the connection is difficult. Gairdner shows students that scientists are people, with great stories and advice who are willing to help students follow their passions.”
GAIRDNER’S 2017 NATIONAL PROGRAM

Gairdner’s National Program is a dynamic and interactive speaker series that brings current and past Canada Gairdner Award laureates to Canada to speak to faculty members and trainees about their research. The Gairdner Foundation celebrates biomedical science research from coast to coast and prides itself on giving Canadians access to scientists from around the world. The National Program has a profound impact on Canadian science culture and innovation. It is the only program of its kind in the world of major awards.

In 2017, Gairdner’s National Program reached 3,400 people at 19 universities

<table>
<thead>
<tr>
<th>Date (2017)</th>
<th>Location</th>
<th>Speaker</th>
<th>Lecture Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 9</td>
<td>Lakehead University</td>
<td>Dr. Adrian Owen, CERC in Cognition and Neuroimaging, Western University; Member Canada Gairdner Award Medical Review Panel</td>
<td>The Search for Consciousness: Detecting Awareness in the Vegetative State</td>
</tr>
<tr>
<td>September 25</td>
<td>Université de Sherbrooke</td>
<td>Dr. Jack Szostak, Professor of Genetics at Harvard Medical School, Cambridge, Mass.</td>
<td>Advances in Nonenzymatic Template-Directed Primer Extension</td>
</tr>
<tr>
<td>October 19-20</td>
<td>University of Lethbridge</td>
<td>Dr. Lewis Kay, 2017 Canada Gairdner International Laureate, University of Toronto</td>
<td>NMR Why Bother? Studies of the p97 Molecular Machine Provide an Answer</td>
</tr>
<tr>
<td>October 20</td>
<td>Université Laval</td>
<td>Dr. Antoine Hakim, 2017 Canada Gairdner Wightman Laureate, University of Ottawa</td>
<td>Présérvéz Votre Vitalité Mentale: Les AVCs et la Démence sont évitables</td>
</tr>
<tr>
<td>October 23</td>
<td>University of British Columbia</td>
<td>Dr. Huda Zoghbi, 2017 Canada Gairdner International Laureate, Baylor College of Medicine, Houston, Texas Dr. Rodolphe Barrangou, 2016 Canada Gairdner International Laureate, North Carolina State University, Raleigh, NC</td>
<td>Protein Levels and Neuropsychiatric Disorders: Insights and Opportunities CRISPR-Cas systems: from adaptive immunity to genome editing machines</td>
</tr>
<tr>
<td>October 23</td>
<td>University of Alberta</td>
<td>Dr. Lewis Kay</td>
<td>NMR Why Bother? Studies of the p97 Molecular Machine Provide an Answer Natural products as probes of the pain pathway: from physiology to atomic structure</td>
</tr>
<tr>
<td>October 23</td>
<td>University of Manitoba</td>
<td>Dr. Lynne Maquat, 2015 Canada Gairdner International Laureate, University of Rochester, Rochester, NY</td>
<td>Nonsense-mediated mRNA decay and human disease: Genome guardian and executor</td>
</tr>
<tr>
<td>October 23</td>
<td>Western University</td>
<td>Dr. Rino Rappuoli, 2017 Canada Gairdner International Laureate, Chief Scientist and Head External R&amp;D, GSK Vaccines, Siena, Italy</td>
<td>Reverse Vaccinology</td>
</tr>
<tr>
<td>October 24</td>
<td>Université de Montréal</td>
<td>Dr. David Julius</td>
<td>Natural products as probes of the pain pathway: from physiology to atomic structure</td>
</tr>
<tr>
<td>Date</td>
<td>University</td>
<td>Speaker</td>
<td>Title</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>October 24</td>
<td>University of Ottawa</td>
<td>Dr. Cesar Victoria, 2017 John Dirks Canada Gairdner Global Health Laureate, Emeritus Professor, Federal University of Pelotas, Pelotas, Brazil</td>
<td>Think locally, act globally - how research carried out in Pelotas contributed to global policies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Antoine Hakim,</td>
<td>A New Era: Stroke is More Treatable, Dementia is More Preventable</td>
</tr>
<tr>
<td>October 24</td>
<td>University of Calgary</td>
<td>Dr. Lewis Kay</td>
<td>NMR Why Bother? Studies of the p97 Molecular Machine Provide an Answer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Huda Zoghbi</td>
<td>Protein Levels and Neuropsychiatric Disorders: Insights and Opportunities</td>
</tr>
<tr>
<td>October 24</td>
<td>University of Waterloo</td>
<td>Dr. Rino Rappuoli</td>
<td>Reverse Vaccinology</td>
</tr>
<tr>
<td>October 24</td>
<td>University of Saskatchewan</td>
<td>Dr. Lynne Maquat</td>
<td>Nonsense-mediated mRNA decay and human disease: Genome guardian and executor</td>
</tr>
<tr>
<td>October 25</td>
<td>McMaster University</td>
<td>Dr. Rino Rappuoli</td>
<td>Reverse Vaccinology</td>
</tr>
<tr>
<td>October 25</td>
<td>University of Guelph</td>
<td>Dr. Frank Plummer, 2016 Canada Gairdner Wightman Laureate, University of Manitoba</td>
<td>The Untold Story of The National Microbiology Laboratory</td>
</tr>
<tr>
<td>October 25</td>
<td>York University</td>
<td>Dr. David Julius</td>
<td>Natural products as probes of the pain pathway: from physiology to atomic structure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lea Harrington, Université de Montréal, Institute of Research in Immunology and Cancer (IRIC), Montréal, QC</td>
<td>Chromatin and stem cell cell fate are impacted globally by short telomeres</td>
</tr>
<tr>
<td>November 1-2</td>
<td>University of New Brunswick</td>
<td>Dr. Janet Rossant, 2015 Canada Gairdner Wightman Laureate, President &amp; Scientific Director, The Gairdner Foundation</td>
<td>Making the Blastocyst-from cells to genes to stem cells</td>
</tr>
<tr>
<td>November 14</td>
<td>McGill</td>
<td>Dr. Lewis Kay</td>
<td>NMR Why Bother? Studies of the p97 Molecular Machine Provide an Answer</td>
</tr>
<tr>
<td>November 15-16</td>
<td>Memorial University</td>
<td>Dr. Lewis Kay</td>
<td>NMR Why Bother? Studies of the p97 Molecular Machine Provide an Answer</td>
</tr>
</tbody>
</table>

Laureate Impact: Dr. Rodolphe Barrangou, 2016 Canada Gairdner International Award laureate

"It is a unique opportunity for the speakers to reach out to Canadian students across provinces and get a personal feel for the breadth and depth of Canadian research and education. Engaging with students was extremely rewarding - a reminder of why I chose a research career in the first place!"
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Session/presentation title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00– 9:10 a.m.</td>
<td>Janet Rossant, President &amp; Scientific Director, The Gairdner Foundation, Toronto</td>
<td>Welcome Remarks</td>
</tr>
<tr>
<td>9:05– 9:10 a.m.</td>
<td>Brenda Andrews, Ph.D. University Professor, C.C., FRSC, Charles H. Best Chair of Medical Research University of Institutions, University of Toronto</td>
<td>Chair’s Remarks</td>
</tr>
<tr>
<td>9:10 - 9:40 a.m.</td>
<td>Lewis Kay, Professor, Departments of Molecular Genetics, Biochemistry and Chemistry, University of Toronto; Senior Scientist, The Hospital for Sick Children, Toronto, Ontario</td>
<td>Wrestling with Heisenberg to Capture the Beautiful Dance of Protein Molecules in Health and Disease</td>
</tr>
<tr>
<td>9:40– 10:10 a.m.</td>
<td>Rino Rappuoli, Chief Scientist and Head External R&amp;D at GSK Vaccines, Siena, Italy</td>
<td>Reverse Vaccinology</td>
</tr>
<tr>
<td>10:30– 11:00 a.m.</td>
<td>David Julius, Professor &amp; Chair, Department of Physiology; Morris Herzstein Chair in Molecular Biology and Medicine, UCSF, San Francisco, California</td>
<td>Natural Products as Probes of the Pain Pathway: From Physiology to Atomic Structure</td>
</tr>
<tr>
<td>11:00 – 11:30 a.m.</td>
<td>Akira Endo, President, Biopharm Research Laboratories; Distinguished Professor Emeritus, Tokyo University of Agriculture and Technology, Tokyo, Japan</td>
<td>Discovery and development of statins (Lecture by Dr. Keiji Hasumi)</td>
</tr>
<tr>
<td>1:00 – 1:05 p.m.</td>
<td>Lea Harrington, Ph.D. Principal Investigator, LIRIC Professor, Department of Medicine, Faculty of Medicine, Université de Montréal</td>
<td>Chair Remarks</td>
</tr>
<tr>
<td>1:05 – 1:35 p.m.</td>
<td>Huda Zoghbi, Professor, Baylor College of Medicine; Investigator, Howard Hughes Medical Institute; Director, Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, Texas</td>
<td>The Story of Rett Syndrome and the insight it provides into Neuropsychiatric Disorders</td>
</tr>
<tr>
<td>1:35– 2:05 p.m.</td>
<td>Antoine Hakim, Emeritus Professor, Neurology, University of Ottawa, Ottawa, Ontario</td>
<td>It Took A Village, but Stroke is Now More Treatable</td>
</tr>
<tr>
<td>2:05– 2:35 p.m.</td>
<td>Cesar Victora, Emeritus Professor, Federal University of Pelotas, Pelotas, Brazil</td>
<td>Think locally, act globally- how research carried out in Pelotas contributed to global policies</td>
</tr>
<tr>
<td>2:35– 2:45 p.m.</td>
<td>Janet Rossant</td>
<td>Concluding Remarks</td>
</tr>
<tr>
<td>Time</td>
<td>Speaker</td>
<td>Titles</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>9:00 – 9:10 a.m.</td>
<td><strong>Janet Rossant</strong>, President &amp; Scientific Director, The Gairdner Foundation, Toronto, Ontario</td>
<td>Opening Session – Welcome Remarks</td>
</tr>
<tr>
<td>9:10– 9:15 a.m.</td>
<td><strong>Dr. Mansour Husain</strong>, Director, Toronto General Hospital Research Institute, Executive Director, Ted Rogers Centre for Heart Research, Toronto</td>
<td>Chairs Remarks</td>
</tr>
<tr>
<td>9:15 – 9:45 a.m.</td>
<td><strong>Emma Allen-Vercoe</strong>, PhD, Professor, University of Guelph; CSO, NuBiyota LLC</td>
<td>Bugs as drugs: modifying the human gut microbiome with ‘microbial ecosystem therapeutics’</td>
</tr>
<tr>
<td>9:45 – 10:10 a.m.</td>
<td><strong>Michael A. Laflamme</strong>, MD, PhD Senior Scientist, University Health Network</td>
<td>Heart regeneration with pluripotent stem cells</td>
</tr>
<tr>
<td>10:35 – 11:05 a.m.</td>
<td><strong>Hans Clevers</strong>, MD, PhD, Professor of Molecular Genetics, Hubrecht Institute, Director Research, Princess Maxima Center for Pediatric Oncology</td>
<td>Stem cell-grown organoids as models for human disease</td>
</tr>
<tr>
<td>11:05 – 11:35 a.m.</td>
<td><strong>Helen H. Hobbs</strong>, Investigator, HHMI Director, McDermott Center for Human Growth and Development University of Texas Southwestern Medical Center</td>
<td>Simple genetics for a complex disease: getting to the heart of the matter</td>
</tr>
<tr>
<td>11:50 – 11:55 p.m.</td>
<td><strong>Bradley G. Wouters</strong>, Senior Scientist, Princess Margaret Cancer Centre: Executive Vice President, Science and Research, University Health Network</td>
<td>Chair Remarks</td>
</tr>
<tr>
<td>11:55 – 12:25 p.m.</td>
<td><strong>Prof. Adrian R. Krainer</strong>, PhD, Cold Spring Harbor Laboratory</td>
<td>Nusinersen (SpinrazaTM): The First FDA Approved Treatment for SMA</td>
</tr>
<tr>
<td>12:25 – 12:55 p.m.</td>
<td><strong>Michel Sadelain</strong>, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center</td>
<td>Therapeutic T cell engineering: CD19 CAR therapy and beyond</td>
</tr>
<tr>
<td>12:55 – 1:00 p.m.</td>
<td><strong>Janet Rossant</strong></td>
<td>Closing Remarks</td>
</tr>
<tr>
<td></td>
<td><strong>Total attendance (Thursday, Friday symposia)</strong></td>
<td>1,026</td>
</tr>
<tr>
<td></td>
<td><strong>Total webcast subscribers (Thursday, Friday symposia)</strong></td>
<td>1,012</td>
</tr>
</tbody>
</table>
ADDITIONAL GAIRDNER PROGRAMMING ACROSS CANADA

Inaugural Canada Gairdner Public Lecture Series
Gairdner hosted its inaugural public lecture series with three events featuring current and past Canada Gairdner Award laureates

Dr. Antoine Hakim, 2017 Canada Gairdner Wightman Award Laureate
“Ne laissez pas s’éteindre votre cerveau”
October 19, 2018
Coeur des sciences, Université du Québec à Montréal. Montréal
Attendance: 350 (sold out audience)

Dr. Eric Kandel, 1987 Canada Gairdner International Award Laureate/2000 Nobel Prize in Physiology or Medicine Laureate
“We are what we remember: Memory and age-related memory loss”
November 19, 2017
Toronto Reference Library. Toronto
Attendance: 400 (sold out audience)

Dr. David Julius, 2017 Canada Gairdner International Award Laureate
Moderated by: Christine Birak, CBC National News Health & Science Reporter
“Peppers, Peppermints and Pit Vipers: How can spices and snakes help us unlock the mysteries of chronic pain?”
December 4, 2017
Ontario Science Centre, Toronto
Attendance: 200

2017 Canada Gairdner Awards Gala
The Canada Gairdner Awards Gala took place on Oct 26 at the Royal Ontario Museum. The Honourable Minister Ginette Petitpas Taylor addressed the audience and brought greetings on behalf of the Prime Minister and the Government of Canada.

Attendance: 500+ representatives of government, academia and industry attended.

CRISPR Unplugged: The Editing Business
Dr. Rodolphe Barrangou, 2016 Canada Gairdner International Award Laureate, Associate Professor of Food Science and the Todd R. Klæhøammer Distinguished Scholar in Probiotics Research at North Carolina State University.
CIBC Live Lounge, MaRS, Toronto
October 25, 2017
The Gairdner Foundation and MaRS hosted a unique conversation about the collision of science and business with leading CRISPR expert, Dr. Rodolphe Barrangou. Audience members learned more about the past, present and future of CRISPR technology and how Dr. Barrangou used his entrepreneurial talents to build and empower businesses during the CRISPR Craze.

Attendance: 80

Launch of the New Gairdner Foundation Website
In 2017, Gairdner launched a new website that promotes user-friendly interactions and enhances our public image. Gairdner also ramped its social media presence and is now sending a quarterly newsletter to stakeholders.
Canada Gairdner Symposium & Public Lecture — University of Alberta: “Molecular Mechanisms of Neurodegeneration and Neuroinflammation”

October 12-13, 2017
Hosted by the University of Alberta in partnership with Alberta Innovates, Alberta Prion Institute and the Alzheimer Society, the symposium covered RNA-dependent mechanisms of neurodegeneration and protein trafficking, misfolded proteins, proteostatic mechanisms autophagy, and mechanisms in an array of neuroinflammatory disorders.

Speakers: Arthur Horwich (Yale University), Richard Morimoto (Northwestern University), David Rubinsztien (Cambridge University), David Westaway and Jack Jhamandas (University of Alberta), Paul Taylor (St. Judes Research Hospital), Phillip Barker and Lynn Raymond (University of British Columbia), Jean-Pierre Julien (Université Laval), Hilmar Bading (Heidelberg), Stuart Lipton (The Scripps Institute), Jeffrey Rothstein (Johns Hopkins), Lorraine Kalia (University of Toronto), Bruce Trapp (Cleveland Clinic), Alexandre Pratt (University of Montreal), and V. Wee Yong (University of Calgary).

Attendance: 175

Public Lecture: “Hope and Innovation: changing the future for patients with brain disease”

October 11, 2017
In partnership with University Hospital Foundation and the University of Alberta Faculty of Medicine and Dentistry, the public lecture engaged Albertans in a discussion on neuroscience and the future of brain disease research.

Speakers: Jack Jhamandas (University of Alberta), Richard Morimoto (Northwestern University) and Roger Marple (Alzheimer Society Hope Advocate).

Attendance: 160

Canada Gairdner Symposium - University of Calgary: “Precision Medicine in Chronic Inflammatory Diseases”

November 9-10, 2017
This two day symposium featured world-renowned academic and industrial experts in precision medicine and microbiome research. The focus was on precision medicine and the role of the microbiome in host immune cell development and function during health and disease including during infections, inflammation, and chronic disease. Integrated within this symposium, were presentations and a panel discussion from microbiome industry representatives.

Speakers: Lee Hood (Institute for Systems Biology, Seattle), Martin Blaser (NYU School of Medicine), Kevin Maloy (Oxford), Paul Kubes (University of Calgary), Gwen Randolph (Washington University in St. Louis) and Henrique Velga-Fernandes (Champilimaud Research, Portugal)

After the presentations, the official opening of the Western Canadian Microbiome Centre (WCMC) took place in the HRIC atrium followed by a public lecture by Dr. Kathy McCoy, director of the germ free facility in the WCMC: "The Power of the Human Microbiome".

Attendance: 420

Partnership Announcement: Gairdner Foundation & Government of Québec

The Gairdner Foundation signed a new three-year $300,000 ($100,000/year) partnership agreement with Fonds de recherche du Québec- Santé and the Government of Québec in May, 2017. The agreement supports Québec-based National, Student Outreach and public lecture programs and represents Gairdner’s third partnership with a provincial government.
GAIRDNER THANKS ITS 2017 SUPPORTERS

The Gairdner Foundation thanks its supporters for making our coast-to-coast programming possible.

GSK Canada
Harry & Evelyn Rosen
Burroughs Wellcome Fund
Merck Canada Inc.

OICR
Sanofi Pasteur
University Health Network

Western University
Mitchell and Kathryn Baran
Family Foundation

THE GLOBE AND MAIL

LONDON DRUGS

RBC Foundation

UNIVERSITY OF TORONTO

CIHR IRSC
Canadian Institutes of Health Research
Instituts de recherche en santé du Canada

Ontario

Alberta

TELU S Health

Québec

Fonds de recherche Santé
THE YEAR AHEAD: OBJECTIVES FOR 2018

The Canada Gairdner Awards have a long, successful record of accomplishment and Gairdner's National and Student Outreach programs are mature and stable. In 2018 and beyond, Gairdner will focus on increasing the reach of our programs and bringing extraordinary science to new demographics including the general public and groups that are underrepresented in the scientific arena. In addition, Gairdner will continue to work with its university partners to evaluate our lecture programs and use the feedback to improve our offerings to ensure they are relevant, focused and meaningful.

Performance Goals for 2018

1. Increase the reach of the National and Student Outreach Program
   • In 2018, Gairdner will seek to bring more attendees into its lectures by hosting regional lectures and providing webcast lectures to remote and rural communities.

2. Evaluate our the National and Student Outreach Program
   • In 2018, Gairdner will engage in an evaluation of its National and Student Outreach programs to assess their effectiveness and to use best practices from some university partners to bolster other programs.

3. Provide additional public-specific programming and materials
   • Gairdner will build off its success in 2017 to provide enhanced programming for the public including webcasted lectures, public lectures and accessible content on social media.

4. Increase brand recognition through enhanced social media presence
   • Gairdner will continue to build its social following on Twitter and Facebook. It will also engage in a video partnership with Research2Reality that will produce high quality, engaging content for followers.

5. Secure strategic partnerships that support Gairdner’s programming and goals and raise its public profile
   • Gairdner will expand its partnerships to include additional scientific organizations in Canada to promote and execute Gairdner events. Gairdner will partner with The Canadian Student Health Research Forum, science centres, Cœurs des sciences and others to promote world-class science across Canada.

6. Continue to increase the number, quality and diversity of nominations
   • Gairdner will proactively seek nominations from around the globe to increase the diversity of our nominations. Gairdner will engage in strategic partnerships to encourage nominations, will promote the nominations process at all its international receptions and continue to engage in outreach to increase the volume of nominations it receives in 2018.

7. Partner in a special symposium focusing on diversity in science
   • In an effort to promote science to under-represented groups, Gairdner will host a 'diversity in science' symposium to showcase the work of scientists from a variety of backgrounds.
GOVERNANCE

The Gairdner Foundation is governed by a 16 member Board of Directors. The Board is comprised of individuals who bring their expertise from the academic, private and public sectors. Board members are nominated and appointed for a maximum term of 3 years, renewable 3 times. Directors are not compensated for their regular board and committee duties.

The Board is responsible for overseeing the management of the organization, and through its committees, conducts detailed examinations of issues and opportunities. The Directors provide strategic insight and leadership, as well as effective governance for the Foundation and work diligently to maintain and extend the capacity of the Foundation to achieve its goals.

The Board meets a minimum of twice each year. Directors of the Board take their role seriously and to the best of their ability, strive to be active participants in all Board and Committee meetings. During 2017, the Board met four times.

2017 Board of Directors

Dr. D. Lorne Tyrrell  
Board Chair  
Director, Li Ka Shing Institute of Virology  
Edmonton, AB

Dr. Victor Dzau  
President, Institute of Medicine, National Academy of Sciences  
North Carolina

Brandt C. Louie  
Chairman and CEO, H.Y. Louie Co. Limited  
Chair, London Drugs Limited  
Vancouver, BC

Ann McCaig  
Chancellor Emeritus, University of Calgary  
Calgary, AB

Bren Gairdner  
Director  
Calgary, AB

John Risley  
President, Clearwater Fine Foods Inc.  
Chester, NS

Melissa Todd  
Director  
Waterloo, ON

Connie Sugiyama  
President, ConMark Strategy Inc.  
Toronto, ON

Heather Munroe-Blum  
Board Vice-Chair  
Principal Emeritus, McGill University  
Montreal, QC

Dr. Calvin Stiller  
Emeritus Professor, Western University, Board Chair OICR  
London, ON

Darren Entwistle  
President & CEO, TELUS  
Vancouver, BC

Eric Newell  
Chancellor Emeritus, University of Alberta  
Edmonton, AB

Mark Lievonen  
Director  
Toronto, ON

Michael Horgan  
Senior Advisor, Bennett Jones LLP  
Former Deputy Minister, Finance  
Ottawa, ON

John Upton  
Director  
Vancouver, BC

George Cooper  
Counsel, McInnes Cooper  
Former Member of Parliament  
Halifax, NS
Standing Committees of the Board of Directors

<table>
<thead>
<tr>
<th>Standing Committee</th>
<th>Members</th>
<th>Number of meetings/year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Committee of Directors</td>
<td>Lorne Tyrrell, Chair&lt;br&gt;Cal Stiller&lt;br&gt;Heather Munroe-Blum&lt;br&gt;Bren Gairdner</td>
<td>As required</td>
</tr>
<tr>
<td>Audit Committee</td>
<td>Eric Newell, Chair&lt;br&gt;John Upton&lt;br&gt;Michael Horgan&lt;br&gt;Melissa Todd</td>
<td>2-3</td>
</tr>
<tr>
<td>Investment Committee</td>
<td>Brandt Louie, Chair&lt;br&gt;Cal Stiller&lt;br&gt;Eric Newell&lt;br&gt;Bren Gairdner</td>
<td>4</td>
</tr>
<tr>
<td>Governance and Nominating Committee</td>
<td>Michael Horgan, Chair&lt;br&gt;Heather Munroe-Blum&lt;br&gt;John Upton</td>
<td>1 (minimum)</td>
</tr>
<tr>
<td>Fundraising Committee</td>
<td>John Risley, Chair&lt;br&gt;Darren Entwistle&lt;br&gt;Heather Munroe-Blum&lt;br&gt;Ann McCaig</td>
<td>4</td>
</tr>
</tbody>
</table>

2017 Gairdner Foundation Committees (For selection of 2017 laureates)

Medical Review Panel

Lea Harrington  
Professor, Department of Medicine, Université de Montréal; Visiting Professor, Wellcome Trust, University of Edinburgh; Montréal, QC

Jeffrey Weitz  
Executive Director, Thrombosis & Atherosclerosis Research Institute, McMaster University, Hamilton, ON

Sonia Anand  
Professor, Department of Medicine, McMaster University, Hamilton, ON

David Andrews  
Director, Biological Sciences, Sunnybrook Research Institute, Toronto, ON

Barbara Ballermann  
Professor & Chair, Department of Medicine, University of Alberta, Edmonton, AB

Steffany Bennett  
Professor, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON

Benjamin Blencowe  
Director, Donnelly Sequencing Centre, University of Toronto, Toronto, ON

Jacques Côté  
Professor, Dept. of Molecular Biology, Medical Biochemistry & Pathology, Université Laval, Québec City, QC

Daniel Durocher  
Senior Investigator, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON

Anne-Claude Gingras  
Senior Investigator, Lunenfeld-Tanenbaum Research Institute, Toronto, ON

John R. Gordon  
Co-chair, Immunology Research Group, University of Saskatchewan, Saskatoon, SK

Gillian Hawker  
Sir John and Lady Eaton Professor & Chair, Department of Medicine, University of Toronto, Toronto, ON

Geoff Hicks  
Director, Regenerative Medicine, Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, MB

Stephen Jones  
Associate Director & Head, Bioinformatics, Genome Sciences Centre, British Columbia Cancer Research Centre, Vancouver, BC
Pauline Johnson  
Department of Microbiology & Immunology, University of British Columbia, Vancouver, BC

Nada Jabado  
Professor, Department of Pediatrics  
McGill University  
Montreal, QC

Sheena Josselyn  
Senior Scientist, Neurosciences & Mental Health Hospital for Sick Children  
Toronto, ON

Gary Kobinger  
Director, Centre de recherche en infectiologie, Université Laval, Québec City, QC

Dale Laird  
Professor & Canada Research Chair in Gap Junctions and Disease, Schulich School of Medicine, University of Western Ontario, London, ON

Paola Marcato  
Assistant Professor, Department of Pathology, Dalhousie University, Halifax, NS

Tim Murphy  
Professor, Department of Psychiatry, University of British Columbia, Vancouver, BC

Brad Nelson  
Director and Distinguished Scientist, Deeley Research Centre, BC Cancer Research Centre  
Vancouver, BC

Adrian Owen  
Canada Excellence Research Chair in Cognitive Neuroscience and Imaging, The Brain and Mind Institute, Western University, London, ON

Lynne-Marie Postovit  
Co-Director, Basic Research, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB

Michel Tremblay  
Professor, Department of Biochemistry, McGill University, Montréal, QC

Raymund J. Wellinger  
Head, Department of Microbiology & Infectious Diseases, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, QC

Gerry Wright  
Professor, Biochemistry and Biomedical Sciences  
Director, Michael G. DeGroote Institute for Infectious Disease Research, McMaster University  
Hamilton, ON

Terry-Lynn Young  
Associate Professor, Faculty of Medicine Genetics, Memorial University, St. John’s, NL

Gerald Zamponi  
Professor, Cumming School of Medicine, University of Calgary, Calgary, AB

Peter Zandstra  
Professor, Donnelly Centre for Cellular & Biomolecular Research, University of Toronto, Toronto, ON

Medical Advisory Board

Janet Rossant, Chair  
President and Scientific Director, Gairdner Foundation, Toronto, ON

Lea Harrington, Co-Chair, MRP  
Professor, Department of Medicine, Université de Montréal; Visiting Professor, Wellcome Trust, University of Edinburgh; Montréal, QC

Jeffrey Weitz, Co-Chair, MRP  
Executive Director, Thrombosis & Atherosclerosis Research Institute, McMaster University, Hamilton, ON

Adrian Bird  
Buchanan Chair of Genetics, University of Edinburgh, Director, Wellcome Trust Centre for Cell Biology, Edinburgh, UK

Michel Bouvier  
Professor, Biochemistry and Molecular Medicine, Principal Investigator, Institute for Research in Immunology and Cancer, Université de Montréal  
Montreal, QC

Pascale Cossart  
Distinguished Professor, Institut Pasteur, Paris, France

Anne Ephrussi  
Head, Developmental Biology Unit, European Molecular Biology Laboratory  
Heidelberg, Germany

Jeffrey Friedman  
Marilyn M. Simpson Professor, Laboratory of Molecular Genetics, Rockefeller University, New York, NY
Susan Gasser  
*Director, Friedrich Miescher Institute, Basel, Switzerland*

**Philip Hieter**  
*Director, Michael Smith Laboratories, University of British Columbia, Vancouver, BC*

**Jan Hoeijmakers**  
*Professor, Molecular Genetics, Erasmus University Rotterdam, Rotterdam, Netherlands*

**Arthur Horwich**  
*Professor, Yale School of Medicine, New Haven, CT*

**Herbert Jäckle**  
*Director, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany*

**Thomas Jessell**  
*Co-Director, Kavli Institute for Brain Science, Columbia University, New York, NY*

**Fabienne MacKay**  
*Head, School of Biomedical Sciences, University of Melbourne, Victoria, Australia*

**Patrick Maxwell**  
*Regius Professor Physic, University of Cambridge, Cambridge, UK*

**Kazutoshi Mori**  
*Professor, Department of Biophysics, Graduate School of Science, Kyoto University, Kyoto, Japan*

**Jeffrey Ravetch**  
*Theresa & Eugene Lang Professor, Rockefeller University, New York, NY*

**Peter Ratcliffe**  
*Director of Clinical Research, Francis Crick Institute,  
Director, Target Discovery Institute at the University of Oxford  
London, UK*

**Randy Schekman**  
*Professor, Department of Molecular & Cell Biology, University of California Berkeley, Berkeley, CA*

**Michael Salter**  
*Chief of Research, Hospital for Sick Children (SickKids), Toronto, ON*

**Steven Scott**  
*GSK Chair in Neuroscience, Centre for Neuroscience Studies, Queen’s University Kingston, ON*

**Michael Strong**  
*Dean, Schulich School of Medicine & Dentistry, Western University, London, ON*

**Jim Woodgett**  
*Director, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON*

**Richard Wozniak**  
*Professor, Department of Cell Biology, University of Alberta, Edmonton, AB*

---

**Wightman Award Advisory Committee**

**Janet Rossant, Chair**  
*President and Scientific Director, The Gairdner Foundation, Toronto, ON*

**Lorne Babiuk**  
*Vice President (Research), University of Alberta, Edmonton, AB*

**Alistair Buchan**  
*Dean of Medicine & Professor of Stroke Medicine, University of Oxford, Oxford, UK*

**Stephen Collins**  
*Associate Dean, Faculty of Health Sciences, McMaster University, Hamilton, ON*

**David Eidelman**  
*Vice President (Health Affairs) & Dean, Faculty of Medicine, McGill University, Montreal, QC*

**Mona Nemer**  
*Vice-President (Research), University of Ottawa, Ottawa, ON*

**Rémi Quirion**  
*Chief Scientist Officer, Fonds de recherche du Québec, Montréal, QC*

**Trevor Young**  
*Dean, Faculty of Medicine, University of Toronto, Toronto, ON,*
Global Health Award Advisory Committee

Alan Bernstein (Chair)
President, CIFAR, Toronto, ON

Christian Bréchot
President, Global Virus Network (GVN)
Paris, France

Roger Glass
Director, Fogarty International Center, National Institutes of Health, Baltimore, MD

Glenda Gray
President, South African Medical Research Council, Johannesburg, South Africa

Kiyoshi Kurokawa
Professor, National Graduate Institute for Policy Studies, Tokyo, Japan

Rose Leke
Emeritus Professor, Immunology and Parasitology, Faculty of Medicine and Biomedical Sciences, Université de Yaoundé, Yaoundé, Cameroon

Nubia Munoz
Emeritus Professor, National Cancer Institute of Colombia
Lyon, France

Peter Piot
Director of the London School of Hygiene & Tropical Medicine School, and Professor of Global Health
London, UK

K. Srinath Reddy
President, Public Health Foundation of India, Delhi, India

Peter Singer
Chief Executive Officer, Grand Challenges Canada
Toronto, ON

Stephanie Strathdee
Associate Dean, Global Health Sciences, Harold Simon Professor, Chief, Division of Global Public Health, University of California
San Diego, Calif.
2017 FINANCIAL HIGHLIGHTS

The Gairdner Foundation maintains proper financial controls and sound management practices to ensure the best use of its public and private funds. Our external auditors issued an unqualified audit opinion about the Gairdner Foundation financial statements which appear at the end of this report.

In 2008, the Foundation received a $20 Million grant from the Federal government for the purpose of supporting and enhancing the Gairdner International Awards Program. Proceeds from the grant can be used to fund the Foundations’ activities, however only the income from the fund may be used until the funding agreement terminates.

In 2008, the Foundation also received $2 million from the Alberta government for the purpose of expanding the Gairdner Outreach Program in Alberta.

These funds have been invested together with the original family endowment under the guidance of the Investment Committee, and in accordance with the terms of these agreements and prudent governance. The investment policy adopted by the Board has been designed with the principal objective being preservation of capital over the long-term.

Planning and Monitoring Investments

The Foundation has a duty to ensure responsible stewardship of funds. The Investment Committee oversees the management and investment of the Gairdner Foundation funds in compliance with our funding agreements. The Foundation’s funds have been invested with 3 major objectives:

1. Preservation of capital
2. Income to meet the administrative costs and award objectives of the Foundation
3. Growth in the ‘capital’ value of the Portfolio’s assets in real (inflation-adjusted) terms

The investment strategy and policy are reviewed annually and the portfolio is reviewed on a quarterly basis. Based on the Foundation’s investment objectives, risk tolerance, income requirements and liquidity needs, the long term target asset allocation of 35% fixed income, 50% equity and 15% alternative strategies was approved by the Board in the early 2016. The portfolio held 35% cash/fixe income, 51% equities and 14% alternatives at December 31, 2017 and is in compliance with the investment policy statement.

Despite a great deal of uncertainty and volatility in the markets in 2017, the investment portfolio increased from $32.7 million at the end of 2016 to $34.3 million at the end of 2017. Equity markets were strong across all equity classes and financial markets continued to advance globally. Canadian equities posted a 9% return for the year, global equities returned 17.4% and U.S. markets were up by 13.9%. Fixed income also generated an absolute return of 2.5% for the year.

Returns for 2017 were $2.3 million representing an ROI of 7.2% net of fees versus the benchmark of 8.5%, before fees for a similar weighted portfolio. ROI since inception has been $16.0 million, representing an annualized rate of return of 6% net of fees, compared to the benchmark of 6.2% gross of fees. ROI since inception net of fees has been basically equivalent to the benchmark at far lower risk.

Results of Operations

Revenue for the year totaled $3.5 million, comprised of $1.1 million from non-governmental sources and gala table sales (31% compared to 29% in 2016), $1.9 million from government (55% compared to 54% in 2016), and $0.5 million from investment income (14% compared to 17% in 2016). Every year the Foundation seeks sponsors from both the public and private sector.

Revenue increased by $0.3 million over 2016 as a result of increased sponsorship income and government grants of $0.4 million, offset by a reduced investment income of $0.1 million. Portfolio returns were reduced by historically low interest rates on fixed income investments.

Expenditures were $2.8 million for the year, an increase of $0.3 million from 2016, due to an increased number of events, communications and marketing as well as compensation.
Compliance Audit

In 2017, the Foundation completed the compliance audit as required under the agreement with CIHR. The Audit objective was to demonstrate the Gairdner Foundation’s compliance with the terms of the agreement between the Foundation and CIHR dated March 28, 2008. This audit covered 2 fiscal years, 2014 and 2015.

Ernst & Young was engaged to perform and report on Specified Procedures designed to assist CIHR in their assessment of the Foundation’s compliance with the Funding Agreement. The Foundation has identified 32 sections of the agreement for compliance testing and verification. Ernst & Young was able to attest to full compliance for 29 sections, with another three sections partially compliant with minor variances and explanations. CIHR commended the Foundation on our positive results and accepted and approved the report.

Independent Evaluation

In 2017, the Foundation completed the independent evaluation as required under the terms of the agreement with CIHR to evaluate the outcomes and principles in the funding agreement. Questions were designed to evaluate the relevance, effectiveness, actions taken in response to the 2013 evaluation, and the efficiency of the program delivery.

The evaluator concluded that from a public policy perspective, the Awards contribute to positioning Canada’s support for world-class biomedical research, openness to international research collaborations, and encouraging students and trainees to consider careers in biomedical science. As such, the Canada Gairdner Awards program is aligned to the central tenets of the government’s innovation agenda and warrants ongoing public support.

The findings across each of these areas clearly indicate that the Outcomes and Principles in the Foundation’s funding agreement with the federal government are being achieved.

An action plan was developed to address potential improvements and recommendations made in the report. CIHR accepted and approved the report.
GAIRDNER FOUNDATION STAFF as of December 2017

Dr. Janet Rossant, President & Scientific Director
Sommer Wedlock, Vice President & Director of Communications
Penny Balberman, Director of Finance
Catherine Rogers, Financial Accountant
Sarah Devonshire, Project Manager & Executive Coordinator
Shamira Furman, Research Officer
Paige O’Beirne, Manager, Fund Development & Communications

Gairdner employs four full-time employees and three part-time employees.

COMPENSATION

Directors
Directors are not compensated for regular Board and Committee duties. They may, however, be compensated for any reasonable out-of-pocket expenses incurred while performing their duties or attending Foundation meetings.

Senior Officers
For the fiscal year ending December 31, 2017, compensation for senior officers was:

Dr. Janet Rossant, President and Scientific Director $200,000
Sommer Wedlock, Vice President & Director of Communications $152,250
Penny Balberman, Director of Finance $90,000
Financial statements

The Gairdner Foundation
December 31, 2017
Independent auditors’ report

To the Members of
The Gairdner Foundation

We have audited the accompanying financial statements of The Gairdner Foundation, which comprise the statement of financial position as at December 31, 2017, and the statements of operations, changes in net assets and cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management’s responsibility for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of The Gairdner Foundation as at December 31, 2017, and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Ernst & Young LLP
Chartered Professional Accountants
Licensed Public Accountants

Toronto, Canada
May 29, 2018
The Gairdner Foundation

Statement of financial position

As at December 31

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>180,370</td>
<td>360,869</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>127,469</td>
<td>124,815</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>47,965</td>
<td>82,465</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>355,804</td>
<td>568,149</td>
</tr>
<tr>
<td>Capital assets, net [note 4]</td>
<td>12,441</td>
<td>14,700</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>34,674,521</td>
<td>33,290,135</td>
</tr>
</tbody>
</table>

| **Liabilities and net assets** |         |         |
| Current                        |         |         |
| Accounts payable and accrued liabilities | 707,598 | 801,107 |
| **Total current liabilities**  | 707,598 | 801,107 |
| Federal government funding [note 5] | 24,088,957 | 23,332,817 |
| Alberta government funding [note 6] | 2,438,730 | 2,393,152 |
| **Total liabilities**          | 27,235,285 | 26,527,076 |
| Commitments [note 8]           |         |         |
| **Net assets**                 |         |         |
| Unrestricted                   | 500,000 | 500,000 |
| Internally restricted [note 7] | 6,939,236 | 6,263,059 |
| **Total net assets**           | 7,439,236 | 6,763,059 |
| **Total net assets**           | 34,674,521 | 33,290,135 |

See accompanying notes

On behalf of the Board:

Director

Director
The Gairdner Foundation

Statement of operations

Year ended December 31

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment income</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[note 3]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest and dividends</td>
<td>86,372</td>
<td>100,826</td>
</tr>
<tr>
<td>Realized gain on investments</td>
<td>327,767</td>
<td>302,973</td>
</tr>
<tr>
<td>Net change in unrealized gain on investments</td>
<td>74,990</td>
<td>135,230</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>489,129</td>
<td>539,029</td>
</tr>
<tr>
<td>Federal government grant funding [note 5]</td>
<td>931,373</td>
<td>895,912</td>
</tr>
<tr>
<td>Alberta government grant funding [note 6]</td>
<td>127,503</td>
<td>130,758</td>
</tr>
<tr>
<td>Other government grants</td>
<td>879,975</td>
<td>711,302</td>
</tr>
<tr>
<td>Table sales</td>
<td>602,779</td>
<td>640,680</td>
</tr>
<tr>
<td>Other contributions and sponsorships</td>
<td>471,023</td>
<td>295,792</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>3,501,782</td>
<td>3,213,473</td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Awards</td>
<td>700,000</td>
<td>700,000</td>
</tr>
<tr>
<td>National events</td>
<td>741,838</td>
<td>602,136</td>
</tr>
<tr>
<td>Advisory boards</td>
<td>271,653</td>
<td>223,812</td>
</tr>
<tr>
<td>Marketing and communications</td>
<td>162,634</td>
<td>121,180</td>
</tr>
<tr>
<td>Administrative</td>
<td>949,480</td>
<td>888,535</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>2,825,605</td>
<td>2,535,663</td>
</tr>
<tr>
<td><strong>Excess of revenue over expenses for the year</strong></td>
<td>676,177</td>
<td>677,810</td>
</tr>
</tbody>
</table>

See accompanying notes
The Gairdner Foundation

Statement of changes in net assets

Year ended December 31

<table>
<thead>
<tr>
<th>2017</th>
<th>Unrestricted</th>
<th>Internally restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>[note 7]</td>
<td>$</td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>Balance, beginning of year</td>
<td>500,000</td>
<td>6,263,059</td>
<td>6,763,059</td>
</tr>
<tr>
<td>Excess of revenue over expenses for the year</td>
<td>676,177</td>
<td>—</td>
<td>676,177</td>
</tr>
<tr>
<td>Interfund transfer [note 7]</td>
<td>(676,177)</td>
<td>676,177</td>
<td>—</td>
</tr>
<tr>
<td>Balance, end of year</td>
<td>500,000</td>
<td>6,939,236</td>
<td>7,439,236</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2016</th>
<th>Unrestricted</th>
<th>Internally restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>[note 7]</td>
<td>$</td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>Balance, beginning of year</td>
<td>500,000</td>
<td>5,585,249</td>
<td>6,085,249</td>
</tr>
<tr>
<td>Excess of revenue over expenses for the year</td>
<td>677,810</td>
<td>—</td>
<td>677,810</td>
</tr>
<tr>
<td>Interfund transfer [note 7]</td>
<td>(677,810)</td>
<td>677,810</td>
<td>—</td>
</tr>
<tr>
<td>Balance, end of year</td>
<td>500,000</td>
<td>6,263,059</td>
<td>6,763,059</td>
</tr>
</tbody>
</table>

See accompanying notes
The Gairdner Foundation

Statement of cash flows

Year ended December 31

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operating activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excess of revenue over expenses for the year</td>
<td>676,177</td>
<td>677,810</td>
</tr>
<tr>
<td>Add (deduct) non-cash items</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amortization of capital assets</td>
<td>8,618</td>
<td>8,704</td>
</tr>
<tr>
<td>Reinvested investment income</td>
<td>489,129</td>
<td>539,029</td>
</tr>
<tr>
<td>Government funding recognized as revenue</td>
<td>(1,058,876)</td>
<td>(1,026,670)</td>
</tr>
<tr>
<td>Changes in non-cash working capital balances related to operations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>(2,654)</td>
<td>13,924</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>34,500</td>
<td>(71,448)</td>
</tr>
<tr>
<td>Accounts payable and accrued liabilities</td>
<td>(93,509)</td>
<td>(66,074)</td>
</tr>
<tr>
<td><strong>Cash used in operating activities</strong></td>
<td>(924,873)</td>
<td>(1,002,783)</td>
</tr>
<tr>
<td><strong>Investing activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchase of capital assets</td>
<td>(6,359)</td>
<td>(4,998)</td>
</tr>
<tr>
<td>Withdrawals from investments held by third parties</td>
<td>750,733</td>
<td>1,100,721</td>
</tr>
<tr>
<td><strong>Cash provided by investing activities</strong></td>
<td>744,374</td>
<td>1,095,723</td>
</tr>
<tr>
<td><strong>Net increase (decrease) in cash during the year</strong></td>
<td>(180,499)</td>
<td>92,940</td>
</tr>
<tr>
<td>Cash, beginning of year</td>
<td>360,869</td>
<td>267,929</td>
</tr>
<tr>
<td><strong>Cash, end of year</strong></td>
<td>180,370</td>
<td>360,869</td>
</tr>
</tbody>
</table>

See accompanying notes
The Gairdner Foundation

Notes to financial statements

December 31, 2017

1. Purpose of the organization

The Gairdner Foundation [the “Foundation”] provides awards to medical scientists in recognition of outstanding discoveries and contributions to medical science, and as an incentive to those who follow in their footsteps. In addition to encouraging and rewarding individuals, the Foundation presents the Gairdner Awards in order to focus public, professional and scientific attention on significant achievements in the field of health sciences.

The Foundation, was incorporated under the laws of Ontario until October 2, 2013 and is currently incorporated under the Canada Not-for-profit Corporations Act. The Foundation is registered as a charitable organization under the Income Tax Act (Canada) [the “Act”] and, as such, is exempt from income taxes and is able to issue donation receipts for income tax purposes.

2. Summary of significant accounting policies

These financial statements are prepared in accordance with Part III of the CPA Canada Handbook – Accounting, which sets out generally accepted accounting principles for not-for-profit organizations in Canada and includes the significant accounting policies set out below.

Cash and cash equivalents

Cash and cash equivalents consist of cash on deposit and short-term investments with maturities of less than 90 days at the date of purchase. Cash and cash equivalents exclude amounts that are managed for returns rather than being held for liquidity.

Financial instruments

Investments reported at fair value consist of equity instruments that are quoted in an active market as well as investments in pooled funds and any investments in fixed income securities that the Foundation designates upon purchase to be measured at fair value. Transaction costs are recognized in the statement of operations in the period during which they are incurred.

Investments in fixed income securities not designated to be measured at fair value are initially recorded at fair value net of transaction costs and are subsequently measured at amortized cost using the straight-line method, less any provision for impairment.

All transactions are recorded on a trade date basis.

Other financial instruments, including accounts receivables, and accounts payable and accrued liabilities, are initially recorded at their fair value and are subsequently measured at cost, net of any provisions for impairment.
The Gairdner Foundation

Notes to financial statements

December 31, 2017

Capital assets
Capital assets are recorded at acquisition cost less accumulated amortization. Contributed capital assets are recorded at fair value at the date of contribution. Amortization is recorded in the accounts at rates intended to write off the cost of the assets over their estimated useful lives.

Rates and methods of amortization are as follows:

<table>
<thead>
<tr>
<th>Asset</th>
<th>Years</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office equipment</td>
<td>5</td>
<td>straight-line</td>
</tr>
<tr>
<td>Computer equipment</td>
<td>3</td>
<td>straight-line</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>Term of lease</td>
<td>straight-line</td>
</tr>
</tbody>
</table>

Revenue recognition
The Foundation follows the deferral method of accounting for contributions, which include grants and donations. Grants and bequests are recognized when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Other donations are recorded when received, since pledges are not legally enforceable claims. Unrestricted contributions are recognized as revenue when initially recorded in the accounts. Externally restricted contributions are deferred when initially recorded in the accounts and recognized as revenue in the year in which the related expenses are recognized. Sponsorships and related event revenue are recognized when the event takes place.

Investment income (loss), which consists of interest, dividends, income distributions from pooled funds, and realized and unrealized gains and losses, net of safekeeping and investment management expenses, is recorded as revenue in the statement of operations, except to the extent that it relates to restricted contributions, in which case it is added directly to those balances.

Foreign currency translation
Transactions denominated in foreign currencies are translated into Canadian dollars at exchange rates prevailing at the transaction date. Monetary assets and liabilities are translated into Canadian dollars at exchange rates in effect as at the balance sheet date. Non-monetary assets and liabilities are translated at the historical rate. Exchange gains and losses are included in the statement of operations except to the extent that they relate to investments, in which case they are accounted for consistent with investment income (loss).

Contributed materials and services
Because of the difficulty in determining fair value, contributed materials and services are not recognized in the financial statements.
3. Investments

Investments consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>%</th>
<th>2016</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>1,445,276</td>
<td>4.2</td>
<td>1,496,286</td>
<td>4.6</td>
</tr>
<tr>
<td>Bonds</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canadian</td>
<td>8,802,000</td>
<td>25.7</td>
<td>9,059,000</td>
<td>27.7</td>
</tr>
<tr>
<td>International</td>
<td>1,896,000</td>
<td>5.5</td>
<td>1,286,000</td>
<td>3.9</td>
</tr>
<tr>
<td>Equities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canadian</td>
<td>6,031,000</td>
<td>17.6</td>
<td>5,656,000</td>
<td>17.3</td>
</tr>
<tr>
<td>US</td>
<td>6,223,000</td>
<td>18.1</td>
<td>6,769,000</td>
<td>20.7</td>
</tr>
<tr>
<td>Other international</td>
<td>5,006,000</td>
<td>14.6</td>
<td>3,573,000</td>
<td>10.9</td>
</tr>
<tr>
<td>Hedge funds</td>
<td>4,903,000</td>
<td>14.3</td>
<td>4,868,000</td>
<td>14.9</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>34,306,276</td>
<td>100.0</td>
<td>32,707,286</td>
<td>100.0</td>
</tr>
</tbody>
</table>

Investments in pooled funds have been included above based on their underlying asset mix.

As at December 31, 2017, bonds have an average term to maturity of 5.1 years [2016 – 4.3 years] and a weighted average yield of 3.37% [2016 – 3.0%].

Investment income recorded in the statement of operations is calculated as follows:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>Interest and dividends</td>
<td>594,714</td>
<td>678,911</td>
</tr>
<tr>
<td>Realized gain on investments</td>
<td>1,574,559</td>
<td>1,526,551</td>
</tr>
<tr>
<td>Net change in unrealized gain on investments</td>
<td>360,243</td>
<td>681,367</td>
</tr>
<tr>
<td>Total investment income</td>
<td>2,529,516</td>
<td>2,886,829</td>
</tr>
<tr>
<td>Less safekeeping and investment management expenses</td>
<td>(179,793)</td>
<td>(170,890)</td>
</tr>
<tr>
<td>Investment income, net of safekeeping and investment management expenses</td>
<td>2,349,723</td>
<td>2,715,939</td>
</tr>
<tr>
<td>Less investment income related to:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Federal government funding [note 5]</td>
<td>(1,687,513)</td>
<td>(1,971,535)</td>
</tr>
<tr>
<td>Alberta government funding [note 6]</td>
<td>(173,081)</td>
<td>(205,375)</td>
</tr>
<tr>
<td><strong>Investment income recognized in revenue</strong></td>
<td>489,129</td>
<td>539,029</td>
</tr>
</tbody>
</table>
The Gairdner Foundation

Notes to financial statements

December 31, 2017

4. Capital assets

Capital assets consist of the following:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$</td>
<td>$</td>
</tr>
<tr>
<td>Computer equipment</td>
<td>20,205</td>
<td>14,901</td>
</tr>
<tr>
<td>Office equipment</td>
<td>25,100</td>
<td>20,000</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>6,871</td>
<td>4,834</td>
</tr>
<tr>
<td></td>
<td>52,176</td>
<td>39,735</td>
</tr>
</tbody>
</table>

5. Federal government funding

The Foundation received a $20,000,000 grant from the federal government in 2008 for the purpose of supporting and enhancing the Gairdner International Awards Program. This grant is to be invested for the duration of the funding agreement and only the income, which includes interest, dividends and realized gains/losses, may be used to support the Foundation’s activities until the funding agreement terminates. The Foundation can draw upon the capital to a maximum of $2,000,000 over the term of the funding agreement, provided it uses best efforts to restore any capital withdrawn.

The funding agreement terminates on March 31, 2028, unless terminated earlier, or renewed in accordance with the funding agreement. Upon termination, the Foundation may use the unspent balance of the original grant as it deems appropriate.
The changes in the Government of Canada funding balance are as follows:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance, beginning of year</td>
<td>23,332,817</td>
<td>22,257,194</td>
</tr>
<tr>
<td>Interest and dividends</td>
<td>297,986</td>
<td>368,779</td>
</tr>
<tr>
<td>Realized gain on investments</td>
<td>1,130,809</td>
<td>1,108,143</td>
</tr>
<tr>
<td>Net change in unrealized gain on investments</td>
<td>258,718</td>
<td>494,613</td>
</tr>
<tr>
<td>Investment income for the year [note 3]</td>
<td>1,687,513</td>
<td>1,971,535</td>
</tr>
<tr>
<td>Amount recognized as revenue</td>
<td>(931,373)</td>
<td>(895,912)</td>
</tr>
<tr>
<td>Balance, end of year</td>
<td>24,088,957</td>
<td>23,332,817</td>
</tr>
</tbody>
</table>

As at December 31, 2017, the amount available for spending in future years is $2,131,004 [2016 – $1,633,582].

6. Alberta government funding

The Foundation received $2,000,000 from the Alberta government in 2008 for the purpose of expanding the Alberta Gairdner Outreach Program. The funds received from the Alberta government are to be invested during the term of the funding agreement, and only the income, which includes interest, dividends and realized gains/losses, may be used to support the Alberta Gairdner Outreach Program. The Foundation can draw upon the capital to a maximum of $250,000 over the term of the funding agreement, provided it uses best efforts to restore any capital withdrawn.

The grant has an indeterminate term; however, the funding agreement is to be reviewed at least every five years. The Alberta government has the right to terminate the agreement, without cause, upon giving 90 days’ notice. Upon termination, the remaining balance of the fund not previously committed for outreach activities must be repaid.

The changes in the Alberta Government funding balance are as follows:

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance, beginning of year</td>
<td>2,393,152</td>
<td>2,318,535</td>
</tr>
<tr>
<td>Interest and dividends</td>
<td>30,563</td>
<td>38,416</td>
</tr>
<tr>
<td>Realized gain on investments</td>
<td>115,982</td>
<td>115,435</td>
</tr>
<tr>
<td>Net change in unrealized gain on investments</td>
<td>26,536</td>
<td>51,524</td>
</tr>
<tr>
<td>Investment income for the year [note 3]</td>
<td>173,081</td>
<td>205,375</td>
</tr>
<tr>
<td>Amount recognized as revenue</td>
<td>(127,503)</td>
<td>(130,758)</td>
</tr>
<tr>
<td>Balance, end of year</td>
<td>2,438,730</td>
<td>2,393,152</td>
</tr>
</tbody>
</table>

As at December 31, 2017, the amount available for spending in future years is $235,011 [2016 – $215,968].
The Gairdner Foundation

Notes to financial statements

December 31, 2017

7. Internally restricted net assets

Internally restricted net assets are funds set aside by the Board of Directors to invest in order to earn income to help fund future operating expenses. In 2017, the Board of Directors approved an interfund transfer from unrestricted to internally restricted net assets of $676,177 [2016 – $677,810]. The Board of Directors may approve a transfer from internally restricted net assets, if required, to fund unanticipated deficits from fundraising shortfalls or unanticipated expenditures.

8. Commitments

The Foundation is required to make future minimum annual lease payments for its premises as follows:

<table>
<thead>
<tr>
<th></th>
<th>$</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>75,000</td>
</tr>
<tr>
<td>2019</td>
<td>37,500</td>
</tr>
<tr>
<td></td>
<td>112,500</td>
</tr>
</tbody>
</table>

9. Financial instruments

The Foundation is exposed to various financial risks through transactions in financial instruments.

Currency risk

The Foundation is exposed to currency risk with respect to its investments denominated in foreign currencies, because the fair value and future cash flows will fluctuate due to the changes in the relative value of foreign currencies against the Canadian dollar.

Interest rate risk

The Foundation is exposed to interest rate risk with respect to its investments in fixed income investments and pooled funds that hold fixed income securities because the fair value will fluctuate due to changes in market interest rates.

Other price risk

The Foundation is exposed to other price risk through changes in market prices [other than changes arising from interest rate or currency risks] in connection with its investments in equity securities and pooled funds.